Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes

• Main Authors: Shieh Shwn-Huey, Probst Janice C, Sung Fung-Chang, Tsai Wen-Chen, Li Ya-Shin, Chen Chih-Yi
• Format: Article
• Language: English
• Published: BMC 2012-05-01
• Series: BMC Cancer
• Subjects: Lung cancer; Comorbidity; Diabetes; Survival; Tuberculosis
• Online Access: http://www.biomedcentral.com/1471-2407/12/174

<p>Abstract</p> <p>Background</p> <p>Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients.</p> <p>Methods</p> <p>The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis.</p> <p>Results</p> <p>On average, the survival time was slightly longer among women than among men (838 ± 689 vs. 749 ± 654 days, <it>p</it> = 0.050). Survival days increased with age (from 580 ± 526 [≤ 50 years] to 803 ± 693 [≥ 71 years] days, <it>p</it> = 0.020) and decreased with stage (from 1224 ± 656 [stage I] to 489 ± 536 [stage IV] days, <it>p</it> < 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, <it>p</it> = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes.</p> <p>Conclusions</p> <p>Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.</p>